团队协作评估与减少多重用药:随机对照试验研究方案
本研究为多中心随机对照试验,计划招募360名70岁及以上、服用五种及以上药物的老年人,评估TAPER结构化临床路径(整合循证工具与患者优先偏好)对减少不适当多重用药的效果,主要结局为药物数量,随访6个月。
要点
- TAPER干预由药师和医生 multidisciplinary 药物审查,结合患者优先偏好。
- 主要结局为药物数量,次要结局为多重用药相关健康结局。
- 对照组为等待名单,最终评估后接受干预。
核心结论
- TAPER干预旨在减少不适当多重用药,并记录患者治疗目标和优先偏好。
研究设计与样本
- 多中心随机对照试验,主要实施点为安大略省汉密尔顿。
- 招募70岁及以上、服用五种及以上药物的老年人,共360名。
- 参与者随机分配至对照组或干预组,随访至基线后6个月。
关键数值与推荐
- 纳入标准:年龄70岁及以上,服用五种及以上药物。
- 主要结局:药物数量。
- 干预组接受药师和医生 multidisciplinary 药物审查,对照组为等待名单。
临床怎么用
- 在初级保健中引入结构化临床路径以减少多重用药,同时记录患者目标与优先偏好。
局限性
- 研究方案阶段,尚未报告结果数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Polypharmacy in older adults can be associated with negative outcomes including falls, impaired cognition, reduced quality of life, and general and functional decline. It is not clear to what extent these are reversible if the number of medications is reduced. Primary care does not have a systematic approach for reducing inappropriate polypharmacy, and there are few, if any, approaches that account for the patient's priorities and preferences. The primary objective of this study is to test the effect of TAPER (Team Approach to Polypharmacy Evaluation and Reduction), a structured operationalized clinical pathway focused on reducing inappropriate polypharmacy. TAPER integrates evidence tools for identifying potentially inappropriate medications, tapering, and monitoring guidance and explicit elicitation of patient priorities and preferences. We aim to determine the effect of TAPER on the number of medications (primary outcome) and health-related outcomes associated with polypharmacy in older adults. METHODS: We designed a multi-center randomized controlled trial, with the lead implementation site in Hamilton, Ontario. Older adults aged 70 years or older who are on five or more medications will be eligible to participate. A total of 360 participants will be recruited. Participants will be assigned to either the control or intervention arm. The intervention involves a comprehensive multidisciplinary medication review by pharmacists and physicians in partnership with patients. This review will be focused on reducing medication burden, with the assumption that this will reduce the risks and harms of polypharmacy. The control group is a wait list, and control patients will be given appointments for the TAPER intervention at a date after the final outcome assessment. All patients will be followed up and outcomes measured in both groups at baseline and 6 months. DISCUSSION: Our trial is unique in its design in that it aims to introduce an operationalized structured clinical pathway aimed to reduce polypharmacy in a primary care setting while at the same time recording patient's goals and priorities for treatment. TRIAL REGISTRATION: Clinical Trials.gov NCT02942927. First registered on October 24, 2016.
引用
- Mangin D, Lamarche L, Agarwal G, et al. Team approach to polypharmacy evaluation and reduction: study protocol for a randomized controlled trial. Trials. 2021. PMID: 34702336. doi:10.1186/s13063-021-05685-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。